fda glp 1 shortage list What's New in Obesity Treatment? GLP-1 No Longer on FDA's

Discover the pathway to a healthier lifestyle with Plexus Slim Hunger Control

Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated

Co-medication analysis revealed 81 cases with antidepressants, antipsychotics, and benzodiazepines, which may be proxies of mental health comorbidities

Updated Virtual Weight Loss Platform Expands Access to GLP-1 Support and Clinician-Guided Obesity Care Across All 50 StatesSAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- Mochi Health, a physician-founded telehealth company delivering medical weight loss care directly to patients, announced today the launch of its newly upgraded online platform

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

The rate of metabolic bariatric surgery decreased from 2022 to 2023, whereas the use of GLP-1 receptor agonists as anti-obesity medications grew over twofold, a research letter showed